IMMP Stock Overview
A late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. More details
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Immutep Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$1.84 |
52 Week High | AU$3.34 |
52 Week Low | AU$1.66 |
Beta | 1.92 |
11 Month Change | -5.64% |
3 Month Change | -24.28% |
1 Year Change | -2.13% |
33 Year Change | -48.17% |
5 Year Change | 9.52% |
Change since IPO | -95.42% |
Recent News & Updates
Recent updates
Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients
Nov 15Immutep: Positive Efti Treatment Data Leads To Late-Stage Programs
Jul 15Immutep: Realizing The Expected Catalysts, With More To Come
May 01Immutep stock climbs on FDA fast track status for eftilagimod to treat lung cancer subtype
Oct 04Immutep secures €1.8M cash in French government's research tax credit
Sep 23Immutep gets Japanese patent for immunotherapy eftilagimod alpha combo
Aug 30Immutep gets Japanese patent related to autoimmune disease drug candidate IMP761
Jul 06Immutep: Australian Immune-Focused Company, Pureplay LAG3 Player
Jun 12Immutep - LAG3 Checkpoint Receives First FDA Approval; Positive For This LAG3 Pure Play
Mar 21Immutep expands the evaluation of efti into a triple combination therapy, shares down 12%
Jun 21Immutep reveals anti-LAG-3 research program
Jun 08Immutep jumps 9% on Chinese patent for efti in chemo-immunotherapy combination
May 26Immutep completes recruitment in efti mid-stage study in head & neck cancer
Jan 07Immutep secures U.S. patent for Eftilagimod Alpha
Dec 29Shareholder Returns
IMMP | US Biotechs | US Market | |
---|---|---|---|
7D | -12.0% | -6.5% | -1.0% |
1Y | -2.1% | 14.6% | 30.3% |
Return vs Industry: IMMP underperformed the US Biotechs industry which returned 14.6% over the past year.
Return vs Market: IMMP underperformed the US Market which returned 30.3% over the past year.
Price Volatility
IMMP volatility | |
---|---|
IMMP Average Weekly Movement | 7.4% |
Biotechs Industry Average Movement | 9.7% |
Market Average Movement | 6.2% |
10% most volatile stocks in US Market | 15.7% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IMMP has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: IMMP's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1987 | n/a | Marc Voigt | www.immutep.com |
Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg fusion based, which is in clinical development for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma.
Immutep Limited Fundamentals Summary
IMMP fundamental statistics | |
---|---|
Market cap | US$270.03m |
Earnings (TTM) | -US$27.82m |
Revenue (TTM) | US$2.50m |
107.9x
P/S Ratio-9.7x
P/E RatioIs IMMP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IMMP income statement (TTM) | |
---|---|
Revenue | AU$3.84m |
Cost of Revenue | AU$41.55m |
Gross Profit | -AU$37.70m |
Other Expenses | AU$5.01m |
Earnings | -AU$42.72m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.029 |
Gross Margin | -981.42% |
Net Profit Margin | -1,111.87% |
Debt/Equity Ratio | 0.5% |
How did IMMP perform over the long term?
See historical performance and comparison